POS0637 INCIDENCE AND DETERMINANTS ASSOCIATED WITH RETRANSITIONING FROM BIOSIMILAR SB4 TO ORIGINATOR ETANERCEPT

Background: The market entry of the etanercept biosimilar SB4 (BS-ETA) reduced prices; and, therefore, many patients in clinical practice are transitioned from originator etanercept (OR-ETA) to BS-ETA. However, previous studies demonstrated that 2.7-17.1% of patients who transitioned from OR-ETA to BS-SB4, retransitioned to OR-ETA (i.e. restarted originator), which might reduce the (financial) benefits of biosimilars. Insight in the incidence of...